Jason Luke, MD, assistant professor at the University of Chicago Medicine, discusses what he hopes the future of advanced melanoma treatment will look like.
Jason Luke, MD, assistant professor at the University of Chicago Medicine, discusses what he hopes the future of advanced melanoma treatment will look like.
With new agents and combinations, long-term melanoma survival will continue to improve. Luke hopes that the future landscape for advanced melanoma -- and all cancers -- will become similar to managing a chronic disease. To do this, there must be treatments with high efficacy and low toxicity profiles.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
2 Clarke Drive
Cranbury, NJ 08512